Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 99 results for melanoma

  1. Sunlight exposure: risks and benefits (NG34)

    This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.

  2. Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) (IPG155)

    Evidence-based recommendations on photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions). This involves applying (or sometimes injecting) a photosensitising agent and using light to activate it, destroying the tumour cells.

  3. Suspected cancer: recognition and referral (NG12)

    This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.

  4. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

  5. Histological margins: What is the optimal histological excision margin in stage 0 melanoma?

    Histological margins: What is the optimal histological excision margin in stage 0 melanoma? Any explanatory notes(if applicable) For a...

  6. Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)

    This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.

  7. Effectiveness of localised treatments: What is the effectiveness of localised treatment for people with stages III and IV melanoma?

    effectiveness of localised treatment for people with stages III and IV melanoma? Any explanatory notes(if applicable) For a short...

  8. Safety, prognostic and predictive biomarkers: Can biomarkers be used for risk stratification and treatment planning for people with melanoma?

    be used for risk stratification and treatment planning for people with melanoma? Any explanatory notes(if applicable) For a short...

  9. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development [GID-TAG509] Expected publication date: 28 September 2016

  10. Survivorship: What are the experiences of people who are living with, through and beyond a melanoma diagnosis in terms of survivorship and their disease journey?

    are the experiences of people who are living with, through and beyond a melanoma diagnosis in terms of survivorship and their disease...

  11. Surveillance strategies: How frequently should surveillance imaging be conducted, and which imaging modality should be used for people with stage IIB to IIIC melanoma?

    which imaging modality should be used for people with stage IIB to IIIC melanoma? Any explanatory notes(if applicable) For a short...

  12. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver (IPG691)

    Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.

  13. NICE considered that more research is needed to establish the treatment sequence for vemurafenib and ipilimumab in patients who have BRAF V600 mutation-positive melanoma.

    vemurafenib and ipilimumab in patients who have BRAF V600 mutation-positive melanoma. Any explanatory notes(if applicable) This may...